<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608033</url>
  </required_header>
  <id_info>
    <org_study_id>OMS721-IGA-001</org_study_id>
    <nct_id>NCT03608033</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeros Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with
      IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE)
      in g/day at 36 weeks from beginning of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, double-blind, randomized, placebo-controlled, study in patients aged 18
      years and above with a biopsy-confirmed diagnosis of IgAN and with 24-hour UPE that is &gt; 1
      g/day within 6 months prior to Screening or uPCR &gt; 0.75 by spot urine at Screening. During
      the study, all patients will continue optimized renin-angiotensin system (RAS) blockade. The
      study consists of five periods: Screening, Run-In, Initial Treatment (Weeks 1-12), Response
      Evaluation (Weeks 13-36), and Follow-Up (Weeks 37-144). Patients are assessed for
      re-treatment based on their response to 24-hour UPE. Additional treatment may be given to
      patients whose 24-hour UPE is &gt; 1 g/day following the Initial Treatment Period and who
      relapse during the Response Evaluation and Follow-Up periods. Patients may be qualified for
      Open-Label Treatment with OMS721 after Week 72.

      Approximately 450 patients are to enrolled in two groups of 225 patients per arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomized 1:1 to receive OMS721 or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment</measure>
    <time_frame>36 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment related Adverse Events as assessed by CTCAE v 4.0</measure>
    <time_frame>168 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in renal function as determined by the rate of change in estimated glomerular filtration rate (eGFR) up to 144 weeks from beginning of treatment</measure>
    <time_frame>144 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment in the subset of patients with baseline high proteinuria (defined as 24-hour UPE ≥ 2 g/day)</measure>
    <time_frame>36 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-averaged change in urine protein/creatinine ratio (uPCR) through 36 weeks.</measure>
    <time_frame>36 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>OMS721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of OMS721</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of Vehicle (D5W or Saline Solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OMS721</intervention_name>
    <description>Biological: OMS721</description>
    <arm_group_label>OMS721</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle (D5W or saline)</intervention_name>
    <description>5% Dextrose in water or normal saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older at the onset of Screening

          -  Biopsy confirmed diagnosis of IgAN within 8 years prior to Screening

          -  Proteinuria of &gt; 1 g/day within 6 months prior to Screening or uPCR &gt; 0.75 by spot
             urine at Screening

          -  Mean of two proteinuria measurements &gt; 1 g/day at baseline

          -  Estimated glomerular filtration rate of ≥ 30 mL/min/1.73 m2 at Screening and baseline

        Exclusion Criteria:

          -  Treatment with immunosuppressants (e.g., azathioprine or cyclophosphamide), or
             cytotoxic drugs, for IgA within 8 weeks prior to Screening. Treatment with
             immunosuppressants or cytotoxic drugs for IgAN is not allowed during the Run-In
             Period. Treatment with immunosuppressants are allowed if such treatment is for
             indications other than IgAN.

          -  Treatment with eculizumab within 8 weeks prior to Screening. Treatment with eculizumab
             is not allowed during the Run-In Period.

          -  Treatment with systemic corticosteroids within 8 weeks prior to Screening. Treatment
             with systemic corticosteroids is not allowed during the Run-In Period.

          -  Uncontrolled BP, a systolic BP of &gt; 150 mmHg and a diastolic BP of &gt; 100 mmHg at rest
             despite the combination of two or more anti-hypertensives including ACEIs, ARBs, or
             direct renin inhibitors at Screening and baseline

          -  Female patients who are pregnant, breast feeding, or planning to become pregnant up
             through 12 weeks after the last dose of study drug, including possible retreatments

          -  Clinical or biological evidence of Type 1 diabetes mellitus (DM), or poorly controlled
             DM with hemoglobin A1c &gt; 7.5 or with evidence of diabetic nephropathy on biopsy,
             systemic lupus erythematosus, IgA vasculitis (Henoch-Schonlein purpura), secondary
             IgAN, or other renal disease during Screening and Run-In

          -  History of renal transplantation

          -  Have a known hypersensitivity to any constituent of the investigational product

          -  Rapidly progressive glomerulonephritis

          -  Significant abnormalities in clinical laboratory values

          -  History of human immunodeficiency virus (HIV), evidence of immune suppression, active
             HCV infection (patients with positive anti-HCV antibody but a non-detected HCV RNA PCR
             can enroll), HBV infection (patients with positive HBsAg are excluded. For patients
             with isolated positive anti-HBc antibody, HBV DNA test by PCR must be non-detectable
             to enroll).

          -  Diagnosis of a malignancy except for adequately treated and cured basal or squamous
             cell skin cancer, curatively treated in situ disease, or other cancer from which the
             patient has been disease-free for ≥ 5 years

          -  Have received any other investigational drug or device or experimental procedures
             within 30 days of the Screening Visit (SV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Haas</last_name>
    <phone>(206) 676-0886</phone>
    <email>lhaas@omeros.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fay Wang</last_name>
    <phone>(206) 676-0863</phone>
    <email>fwang@omeros.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Crystal Lake</city>
        <state>Illinois</state>
        <zip>60012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Liège</city>
        <state>Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>(206) 676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Banská Bystrica</city>
        <zip>975-17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Haas</last_name>
      <phone>206-676-0886</phone>
      <email>lhaas@omeros.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

